Loading
Loading
Research Overview
Fragment of spadin (TREK-1 channel inhibitor); blocks the TREK-1 two-pore domain potassium channel in hippocampal neurons, producing rapid-onset antidepressant effects in preclinical models by enhancing serotonergic transmission.
PE-22-28 is a short synthetic peptide identified as an optimised fragment of spadin with enhanced TRPC6 channel agonist activity. TRPC6 (transient receptor potential canonical 6) is a calcium-permeable cation channel expressed in neurons, where it has been implicated in dendrite and spine morphogenesis, synaptic plasticity, and the regulation of neuronal excitability. Preclinical research has used PE-22-28 to investigate how pharmacological TRPC6 activation influences neural circuit biology in relevant laboratory model systems.
Preclinical behavioural neuroscience studies have examined PE-22-28 in animal models of depression-like behaviour, motivated by preclinical evidence that TRPC6 signalling intersects with BDNF (brain-derived neurotrophic factor) pathways and neuroplasticity mechanisms implicated in mood regulation biology. Rodent model behavioural assays including forced swim tests and chronic mild stress paradigms have been used to characterise PE-22-28's effects on depression-related endpoints in laboratory settings.
The compound's mechanism of action through TRPC6 activation distinguishes it mechanistically from classical neurotransmitter-based research tools in depression neurobiology, and has been used preclinically to investigate a distinct pathway by which calcium channel activity influences neuroplasticity and synaptic remodelling. These laboratory investigations have contributed to understanding how TRPC6 biology intersects with neurotrophin signalling in mood-related preclinical model systems.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, pe-22-28 (trpc6 agonist) peptide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
PE-22-28 (TRPC6 Agonist) Peptide research is most relevant to protocols examining:
Rapid-onset antidepressant mechanism research
TREK-1 two-pore domain potassium channel biology studies
Serotonergic transmission enhancement investigations
Researchers exploring novel non-SSRI antidepressant targets
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
Fragment of spadin (TREK-1 channel inhibitor); blocks the TREK-1 two-pore domain potassium channel in hippocampal neurons, producing rapid-onset antidepressant effects in preclinical models by enhancing serotonergic transmission.
| Parameter | Value |
|---|---|
| Dose range | 1–3 mg/day |
| Schedule | Daily |
| Route | Subcutaneous, Intranasal |
| Half-life | ~Hours |
primarily preclinical
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.